SOPHiA GENETICS came into this print with momentum, then the stock jumped another 20.2% to close at US$6.84. For a company often treated as a long term growth story with distant profitability, the market reaction reflects how sharply investors responded to the latest revenue and guidance update.

The headline is simple. Q2 2026 delivered strong top line growth to US$23.31 million and management raised full year revenue guidance to a range of US$94 to US$96 million. Losses remain a clear feature of the story, yet for now the market is rewarding the revenue trajectory more than it is worrying about the ongoing red ink.

Is SOPHiA GENETICS now priced for years of 22.2% revenue growth, or has the market pushed its 6.7x P/S ratio too far compared with peers and the healthcare services industry? Compare that premium against the underlying cash generation and business profile on our valuation analysis for SOPHiA GENETICS

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$23.31 million vs. US$18.32 million (up about 27%)
• Net Loss (Q2 2026 vs Q2 2025): US$22.36 million loss vs. US$22.41 million loss (broadly stable year on year)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.30 loss per share vs. US$0.33 loss per share (loss per share narrowed modestly)
• Adjusted EBITDA Loss (Q2 2026 vs Q2 2025): US$8.8 million loss vs. about US$12.1 million loss (improved by roughly 27%)

Tired of scrolling through dense earnings releases and spreadsheets to make sense of SOPHiA GENETICS? Get the full picture of its valuation and fundamentals in a clean visual dashboard with our company report for SOPHiA GENETICS.

Can SOPHiA GENETICS Turn Usage Into Profits?

Bulls argue SOPHiA GENETICS is building a high quality, recurring platform where growing usage and partnerships steadily move the business toward profitability. Q2 gives some backing to that story. Revenue grew 27% with analyses up 22% to 115,000 and the U.S. business and liquid biopsy both posting strong double digit growth. Net dollar retention of 117% and churn below 1% show existing customers are expanding, not just trialing. Adjusted EBITDA loss improved by about 27% to US$8.8 million, while adjusted operating expenses were flat at US$25.6 million despite investment in commercial roles. The AstraZeneca companion diagnostic programs and the Memorial Sloan Kettering joint venture plan support the idea that biopharma and higher value applications can deepen the revenue base. Management still guides to full year adjusted EBITDA losses, yet the combination of usage growth and tighter cost control is moving in the direction bulls want.

Bear Case Tests: Losses, Margins And Execution Risk

Bears focus on persistent losses, margin pressure and execution risk around big partnerships. Q2 does not remove those concerns. The company still reported a sizeable net loss of US$22.36 million and expects a full year adjusted EBITDA loss of US$29 to US$32 million. Gross margin slipped to 64.6% and adjusted gross margin to 72.1% as lower margin pharma and services work and higher cloud and hosting costs weighed on profitability. That challenges the idea that scale automatically lifts margins. Cash burn of US$12.9 million, even after an oversubscribed US$57.5 million capital raise, underlines ongoing funding needs. Many liquid biopsy customers, more than half of 80, are not yet revenue generating, and AstraZeneca and NHS contracts are framed as medium term revenue drivers. The growth engine is working, but the path to self funded expansion still relies on tight execution and improved unit economics.

With SOPHiA GENETICS still reporting sizeable losses, softer margins and many customers not yet revenue generating, the key question is whether these headwinds are isolated growing pains or signals of deeper structural pressure. Review the independent risk analysis for SOPHiA GENETICS which shows 2 important warning signs

Take Control Of Your Next Move

If the latest revenue growth and guidance from SOPHiA GENETICS has caught your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price alongside fair value estimates and watch for a more attractive entry point. Once you decide to take a position, keep your decisions clear and focused with the Portfolio Command Center that surfaces only the key developments affecting your holdings. For a longer term view, tap into the Community to see how other investors are thinking about the same risks and potential catalysts. This way you can spot both emerging opportunities and warning signs early and stay a step ahead of the wider market.

Seeking Alternatives Beyond SOPHiA GENETICS?

Fresh stock ideas can move from under the radar for now to flying once the crowd catches on. Use these screeners before the best entries start dropping. Act now.

• Spot cash rich companies that still trade at appealing levels by scanning a curated list of solid balance sheet and fundamentals stocks (49 results) before the market fully prices in their resilience and momentum. Act early.
• Ride the AI trend without chasing hype by zeroing in on 68 profitable AI stocks that aren't just burning cash that already convert growth into real earnings while it still matters for sensible entry points.
• Turn curiosity into action by filtering for 85 resilient stocks with low risk scores that keep volatility in check so you are not caught reacting after prices have already broken out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.